AurKa Pharma Inc., based in Montréal, Québec, was a special purpose company created to develop one compound to proof-of-concept. The project was fully financed by TVM Life Science Innovation I L.P. The compound was originally discovered through one of Lilly’s research and development programs, with the potential to treat certain types of solid tumors, including small cell lung cancer and treatment resistant breast cancer. Driven by promising Phase 1 data, Lilly subsequently made a competitive early buyout offer, which TVM accepted in May 2018.
Caroline Fortier (CEO)